id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-N-1262-0029,FDA,FDA-2018-N-1262,Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher; EYLEA HD (aflibercept),Notice,Notice of Approval,2025-04-23T04:00:00Z,2025,4,,,2025-04-23T13:35:52Z,2025-06969,0,0,0900006486aa96be
FDA-2018-N-1262-0028,FDA,FDA-2018-N-1262,Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; AMVUTTRA (vutrisiran),Notice,Notice of Approval,2025-04-21T04:00:00Z,2025,4,,,2025-04-21T13:40:16Z,2025-06785,0,0,0900006486aa4378
FDA-2018-N-1262-0027,FDA,FDA-2018-N-1262,Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; TREMFYA (guselkumab),Notice,Notice of Approval,2025-04-21T04:00:00Z,2025,4,,,2025-04-21T13:37:12Z,2025-06784,0,0,0900006486aa43b7
FDA-2018-N-1262-0026,FDA,FDA-2018-N-1262,"Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor)",Notice,Announcement,2025-01-10T05:00:00Z,2025,1,2025-01-10T05:00:00Z,,2025-01-10T13:56:06Z,2025-00341,0,0,09000064868addd8